Gelonghui August 29th 丨 Kedi-B (02487.HK) announced that for the six months ended June 30, 2024, income increased by about 178.3% year-on-year to about 95.6 million yuan; gross margin increased by about 5 percentage points from about 48% for the six months ended December 31, 2023 to about 53% for the six months ended June 30, 2024. For the six months ended June 30, 2024, the adjusted net loss is about 0.161 billion yuan (adjusted for non-international financial reporting standards). The group continues to optimize operational efficiency, and the proportion of adjusted net loss to income is further narrowed.
In terms of the main product CU-40102 (topical finasteride spray), CU-40102 is the world's first and only topical finasteride product approved for the treatment of androgenetic alopecia, and the first topical finasteride product to be accepted by the National Medical Products Administration. Finasteride, as a specific type II 5α-reductase inhibitor, inhibits the conversion of testosterone to dihydrotestosterone in the scalp, and can treat androgenetic alopecia in male patients. Unlike oral finasteride, the topical formulation of CU-40102 allows patients to apply the medication directly and accurately to the surface of the scalp, maintaining high concentration at the site of application, while reducing the side effects often caused by oral medication. The NDA of CU-40102 was accepted by the National Medical Products Administration in January 2024 and submitted to the Hong Kong Department of Health in April 2024.
